Familial Partial LipodystrophySymptoms, Doctors, Treatments, Advances & More
Familial Partial Lipodystrophy Overview
Learn About Familial Partial Lipodystrophy
Familial partial lipodystrophy is a rare condition that is characterized by the loss of fatty (adipose) tissue that is found underneath the skin (subcutaneous). Affected individuals typically lose subcutaneous adipose tissue from the arms; legs; and the truncal region, which includes the chest, abdomen, and hips. Familial partial lipodystrophy is part of a group of disorders known as lipodystrophies, which can cause the loss of varying amounts of adipose tissue. The severity of familial partial lipodystrophy and the specific signs and symptoms that are seen in affected individuals can vary, even among members of the same family.
Genetic changes that cause disease are called pathogenic variants. Pathogenic variants in several different genes cause familial partial lipodystrophy. Pathogenic variants in the lamin A/C (LMNA) gene cause familial partial lipodystrophy type 2. The other forms of the disorder are caused by pathogenic variants in other genes.
Familial partial lipodystrophy is a rare disease that affects 1 in 7,000 to 2.3 in 1 million people. However, the exact prevalence is difficult to determine, as many people with this condition likely do not receive a diagnosis. Women tend to receive a diagnosis of familial partial lipodystrophy more often than men. This may be because the loss of fat from the arms, legs, and hips is more easily recognized in women or because complications, such as diabetes mellitus and hypertriglyceridemia, tend to be more severe in women.
Most cases of familial partial lipodystrophy, including type 2, are inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. In some cases, an affected person inherits the pathogenic variant from a parent. Other cases result from a new (de novo) pathogenic variant in the gene that occurs during the formation of reproductive cells (eggs or sperm) in an affected individual's parent or during early embryonic development. These affected individuals typically have no history of the disorder in their family.
Office Of Smita R. Ramanadham, MD
Smita Ramanadham is a Plastic Surgeon practicing medicine in East Brunswick, New Jersey. Dr. Ramanadham is rated as a Distinguished provider by MediFind in the treatment of Familial Partial Lipodystrophy. She is also highly rated in 3 other conditions, according to our data. Her clinical expertise encompasses Familial Partial Lipodystrophy, Congenital Generalized Lipodystrophy, Breast Enlargement In Males, Keloids, and Pancreaticoduodenectomy. Dr. Ramanadham is board certified in Plastic Surgery, 2015. Dr. Ramanadham is currently accepting new patients.
Domino's Farms
Elif Oral is an Endocrinologist practicing medicine in Ann Arbor, Michigan. Dr. Oral is rated as an Elite provider by MediFind in the treatment of Familial Partial Lipodystrophy. She is also highly rated in 16 other conditions, according to our data. Her clinical expertise encompasses Familial Partial Lipodystrophy, Congenital Generalized Lipodystrophy, Familial Hypertriglyceridemia, Gastric Bypass, and Sleeve Gastrectomy. Dr. Oral is board certified in Endocrinology, Diabetes & Metabolism. Dr. Oral is currently accepting new patients.
Office
Abhimanyu Garg is an Endocrinologist practicing medicine in Dallas, Texas. Dr. Garg is rated as an Elite provider by MediFind in the treatment of Familial Partial Lipodystrophy. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Acrorenal Mandibular Syndrome, Familial Partial Lipodystrophy, Congenital Generalized Lipodystrophy, Familial Hypertriglyceridemia, and Gastric Bypass. Dr. Garg is currently accepting new patients.
Background: People with familial partial lipodystrophy (FPLD) do not store fat in the body normally. This can lead to serious illnesses such as diabetes and heart disease. To learn more about FPLD, researchers want to compare the fat tissue in people with this disease to the fat tissue of healthy people.
Summary: Diagnostic case-control study (1 case for 2 controls). Inclusion of patients with severe insulin resistance syndrome of genetic origin, then inclusion of controls: patients examined for PCOS in day hospital with matching age (+/- 5 years) and Body mass index (+/- 5kg/m2).
Published Date: August 25, 2026
Published By: National Institutes of Health
